The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ryan, 1984, Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases., Am J Med, 77, 501, 10.1016/0002-9343(84)90112-8
Drezner, 1996, 319
Schapira, 1995, Tumor-induced osteomalacia., Semin Arthritis Rheum, 25, 35, 10.1016/S0049-0172(95)80016-6
Cai, 1994, Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia., N Engl J Med, 330, 1645, 10.1056/NEJM199406093302304
Econs, 1994, Tumor-induced osteomalacia-unveiling a new hormone., N Engl J Med, 330, 1679, 10.1056/NEJM199406093302310
Chalew, 1996, Hypophosphatemia induced in mice by transplantation of a tumor-derived cell line from a patient with oncogenic rickets., J Pediatr Endocrinol Metab, 9, 593, 10.1515/JPEM.1996.9.6.593
Tenenhouse, 1998, 5039
1995, A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets., Nat Genet, 11, 130, 10.1038/ng1095-130
Francis, 1997, Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets., Genome Res, 7, 573, 10.1101/gr.7.6.573
Beck, 1997, Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice., J Clin Invest, 99, 1200, 10.1172/JCI119276
Ruchon, 1998, Pex mRNA is localized in developing mouse osteoblasts and odontoblasts., J Histochem Cytochem, 46, 459, 10.1177/002215549804600405
Wang, 1999, A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3., Dev Biol, 96, 4455
Kruse, 2001, Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation., Horm Res, 55, 305
Eicher, 1976, Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets., Proc Natl Acad Sci USA, 73, 4667, 10.1073/pnas.73.12.4667
Meyer Jr, 1989, Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice., J Bone Miner Res, 4, 493, 10.1002/jbmr.5650040407
Portale, 1989, Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men., J Clin Invest, 83, 1494, 10.1172/JCI114043
Berndt, 1992
Gmaj, 1986, Cellular mechanisms of inorganic phosphate transport in kidney., Physiol Rev, 66, 36, 10.1152/physrev.1986.66.1.36
Beck, 1998, Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities., Proc Natl Acad Sci USA, 95, 5372, 10.1073/pnas.95.9.5372
Tenenhouse, 1998, Differential expression, abundance, and regulation of Na+-phosphate cotransporter genes in murine kidney, Am J Physiol, 275, F527
Jones, 2002, Secreted Frizzled-related proteins: searching for relationships and patterns., Bioessays, 24, 811, 10.1002/bies.10136
Rattner, 1997, A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors., Proc Natl Acad Sci USA, 94, 2859, 10.1073/pnas.94.7.2859
Kuhl, 2000, The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape., Trends Genet, 16, 279, 10.1016/S0168-9525(00)02028-X
Malbon, 2004, Frizzleds: new members of the superfamily of G-protein-coupled receptors., Front Biosci, 9, 1048, 10.2741/1308
Patapoutian, 2000, Roles of Wnt proteins in neural development and maintenance., Curr Opin Neurobiol, 10, 392, 10.1016/S0959-4388(00)00100-8
Wang, 2004, Wnt-frizzled signaling to G-protein-coupled effectors., Cell Mol Life Sci, 61, 69, 10.1007/s00018-003-3165-x
Hsieh, 1999, A new secreted protein that binds to Wnt proteins and inhibits their activities., Nature, 398, 431, 10.1038/18899
Gong, 2001, LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development., Cell, 107, 513, 10.1016/S0092-8674(01)00571-2
Boyden, 2002, High bone density due to a mutation in LDL-receptor-related protein 5., N Engl J Med, 346, 1513, 10.1056/NEJMoa013444
Little, 2002, A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait., Am J Hum Genet, 70, 11, 10.1086/338450
Berndt, 2003, Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent., J Clin Invest, 112, 785, 10.1172/JCI18563
De Beur, 2002, Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism., J Bone Miner Res, 17, 1102, 10.1359/jbmr.2002.17.6.1102
Shimada, 2001, Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia., Proc Natl Acad Sci USA, 98, 6500, 10.1073/pnas.101545198
Kurose, 2004, Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma., J Urol, 171, 1314, 10.1097/01.ju.0000101047.64379.d4
Nozaki, 2001, Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer., Int J Oncol, 19, 117
Tsuji, 2001, Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas., Biochem Biophys Res Commun, 289, 257, 10.1006/bbrc.2001.5972
Kobayashi, 2002, Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells., Gene, 282, 151, 10.1016/S0378-1119(01)00838-1
Surendran, 2005, Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis., J Am Soc Nephrol, 16, 2373, 10.1681/ASN.2004110949
Rowe, 2000, MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia., Genomics, 67, 54, 10.1006/geno.2000.6235
Petersen, 2000, Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes., J Biol Chem, 275, 36172, 10.1074/jbc.M003622200
Lu, 2004, Mepe is expressed during skeletal development and regeneration., Histochem Cell Biol, 121, 493, 10.1007/s00418-004-0653-5
Nampei, 2004, Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone., J Bone Miner Metab, 22, 176, 10.1007/s00774-003-0468-9
Argiro, 2001, Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone., Genomics, 74, 342, 10.1006/geno.2001.6553
Fisher, 2003, Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins, Connect Tissue Res, 44, 33, 10.1080/03008200390152061
Igarashi, 2002, In situ localization and in vitro expression of osteoblast/osteocyte factor 45 mRNA during bone cell differentiation., Histochem J, 34, 255, 10.1023/A:1021745614872
MacDougall, 2002, MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21., Connect Tissue Res, 43, 320, 10.1080/03008200290000556
Siggelkow, 2004, Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts., Bone, 35, 570, 10.1016/j.bone.2004.03.033
Zhang, 2004, Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells., Endocrine, 24, 15, 10.1385/ENDO:24:1:015
Liu, 2005, Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia., J Am Soc Nephrol, 16, 1645, 10.1681/ASN.2004121060
Negri, 2004, [Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family.], Medicina (B Aires), 64, 103
Hoyer, 2001, Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals., Kidney Int, 60, 77, 10.1046/j.1523-1755.2001.00772.x
Wesson, 2003, Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules., J Am Soc Nephrol, 14, 139, 10.1097/01.ASN.0000040593.93815.9D
Long, 1998, A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface., Proc Natl Acad Sci USA, 95, 12083, 10.1073/pnas.95.21.12083
Schlesinger, 1977, Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva., J Biol Chem, 252, 1689, 10.1016/S0021-9258(17)40603-X
Guo, 2002, Inhibition of MEPE cleavage by Phex., Biochem Biophys Res Commun, 297, 38, 10.1016/S0006-291X(02)02125-3
Toomes, 1999, Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis., Nat Genet, 23, 421, 10.1038/70525
Rowe, 2004, MEPE has the properties of an osteoblastic phosphatonin and minhibin., Bone, 34, 303, 10.1016/j.bone.2003.10.005
Gowen, 2003, Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass., J Biol Chem, 278, 1998, 10.1074/jbc.M203250200
Hayashibara, 2004, A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo., J Bone Miner Res, 19, 455, 10.1359/JBMR.0301263
Jain, 2004, Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density., J Clin Endocrinol Metab, 89, 4158, 10.1210/jc.2003-032031
Bresler, 2004, Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets, J Endocrinol, 183, R1, 10.1677/joe.1.05989
Jan de Beur, 2004, Matrix extracellular phosphoglycoprotein (MEPE) fragments circulate in excess in patients with tumor-induced osteomalacia (TIO) and X-linked hypophosphatemic rickets, J Bone Miner Res, 19, S101
Rowe, 2005, Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP)., Bone, 36, 33, 10.1016/j.bone.2004.09.015
Econs, 1997, The genetics of osteoporosis and metabolic bone disease., 111
Bianchine, 1971, Familial hypophosphatemic rickets showing autosomal dominant inheritance., Birth Defects, 7, 287
Econs, 1997, Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate wasting disorder., J Clin Endocrinol Metab, 82, 674, 10.1210/jcem.82.2.3765
Econs, 1997, Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13., J Clin Invest, 100, 2653, 10.1172/JCI119809
2000, Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23., Nat Genet, 26, 345, 10.1038/81664
Entesarian, 2005, Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands., Nat Genet, 37, 125, 10.1038/ng1507
Van Swieten, 2003, A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebral ataxia., Am J Hum Genet, 72, 191, 10.1086/345488
White, 2001, The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.[comment]., J Clin Endocrinol Metab, 86, 497, 10.1210/jcem.86.2.7408
Folpe, 2004, Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature., Am J Surg Pathol, 28, 1, 10.1097/00000478-200401000-00001
Larsson, 2003, Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia., Eur J Endocrinol, 148, 269, 10.1530/eje.0.1480269
Shimada, 2002, Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo., Endocrinology, 143, 3179, 10.1210/endo.143.8.8795
Riminucci, 2003, FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting., J Clin Invest, 112, 683, 10.1172/JCI18399
Liu, 2003, Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX., J Biol Chem, 278, 37419, 10.1074/jbc.M304544200
Bowe, 2001, FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate., Biochem Biophys Res Commun, 284, 977, 10.1006/bbrc.2001.5084
White, 2001, Autosomal dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23., Kidney Int, 60, 2079, 10.1046/j.1523-1755.2001.00064.x
Seidah, 1999, Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive peptides., Brain Res, 848, 45, 10.1016/S0006-8993(99)01909-5
Molloy, 1992, Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen., J Biol Chem, 267, 16396, 10.1016/S0021-9258(18)42016-9
Nakayama, 1997, Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins., Biochem J, 327, 625, 10.1042/bj3270625
Levin, 2001, Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients., Curr Opin Nephrol Hypertens, 10, 563, 10.1097/00041552-200109000-00003
Bai, 2003, The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency., J Biol Chem, 278, 9843, 10.1074/jbc.M210490200
Benet-Pages, 2004, FGF23 is processed by proprotein convertases but not by PHEX., Bone, 35, 455, 10.1016/j.bone.2004.04.002
Constam, 1999, Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases., J Cell Biol, 144, 139, 10.1083/jcb.144.1.139
Cui, 1998, BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development., EMBO J, 17, 4735, 10.1093/emboj/17.16.4735
Hendy, 1995, Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin. A mass spectromic study., J Biol Chem, 270, 9517, 10.1074/jbc.270.16.9517
Jonsson, 2003, Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia., N Engl J Med, 348, 1656, 10.1056/NEJMoa020881
Weber, 2003, Serum FGF23 levels in normal and disordered phosphorus homeostasis., J Bone Miner Res, 18, 1227, 10.1359/jbmr.2003.18.7.1227
Yamazaki, 2002, Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia., J Clin Endocrinol Metab, 87, 4957, 10.1210/jc.2002-021105
Aono, 2003, The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice, J Bone Miner Res, 18, S16
Bai, 2002, Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression., Mol Endocrinol, 16, 2913, 10.1210/me.2002-0113
Liu, 2002, Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype., J Biol Chem, 277, 3686, 10.1074/jbc.M107707200
Erben, 2005, Overexpression of human PHEX under the human β-actin promoter does not fully rescue the Hyp mouse phenotype., J Bone Miner Res, 20, 1149, 10.1359/JBMR.050212
Larsson, 2004, Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis., Endocrinology, 145, 3087, 10.1210/en.2003-1768
Shimada, 2004, FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa., Biochem Biophys Res Commun, 314, 409, 10.1016/j.bbrc.2003.12.102
Lotscher, 1996, New aspects of adaptation of rat renal Na-Pi cotransporter to alterations in dietary phosphate., Kidney Int, 49, 1012, 10.1038/ki.1996.146
Shimada, 2004, FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis., J Bone Miner Res, 19, 429, 10.1359/JBMR.0301264
Tenenhouse, 1996, Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice., Kidney Int, 49, 1027, 10.1038/ki.1996.149
Zhang, 2002, Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1α-hydroxylase gene expression in the proximal renal tubule., Endocrinology, 143, 587, 10.1210/endo.143.2.8627
Kahlen, 1994, Identification of a vitamin D receptor homodimer-type response element in the rat calcitriol 24-hydroxylase gene promoter., Biochem Biophys Res Commun, 202, 1366, 10.1006/bbrc.1994.2081
Murayama, 1999, Positive and negative regulations of the renal 25-hydroxyvitamin D3 1α-hydroxylase gene by parathyroid hormone, calcitonin, and 1α,25(OH)2D3 in intact animals., Endocrinology, 140, 2224, 10.1210/endo.140.5.6691
Bai, 2004, Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders., Endocrinology, 145, 5269, 10.1210/en.2004-0233
Shimada, 2004, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism., J Clin Invest, 113, 561, 10.1172/JCI200419081
Sitara, 2004, Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice., Matrix Biol, 23, 421, 10.1016/j.matbio.2004.09.007
Larsson, 2003, Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers., Kidney Int, 64, 2272, 10.1046/j.1523-1755.2003.00328.x
Ferrari, 2004, FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men., J Clin Endocrinol Metab, 90, 1519, 10.1210/jc.2004-1039
Ito, 2005, Vitamin D and phosphate regulate fibroblast growth factor-23 in K562 cells, Am J Physiol Endocrinol Metab, 288, E1101, 10.1152/ajpendo.00502.2004
Yu, 2005, Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations., Bone, 36, 971, 10.1016/j.bone.2005.03.002
Saito, 2005, Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo., J Biol Chem, 280, 2543, 10.1074/jbc.M408903200
Li, 1997, Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia., Proc Natl Acad Sci USA, 94, 9831, 10.1073/pnas.94.18.9831
Gupta, 2004, FGF-23 is elevated by chronic hyperphosphatemia., J Clin Endocrinol Metab, 89, 4489, 10.1210/jc.2004-0724
Hoogendoorn, 2003, Hypophosphatemia, osteomalacia and proximal muscle weakness treated by surgery., Clin Endocrinol (Oxf), 58, 796, 10.1046/j.1365-2265.2003.18012.x
Shulman, 2004, Tumor-induced rickets: usefulness of MR gradient echo recall imaging for tumor localization., J Pediatr, 144, 381, 10.1016/j.jpeds.2003.11.023
Yamazaki, 2003, Elevated circulatory and expression level of fibroblast growth factor (FGF)-23 in hypophosphatemic mice, Bone, 32, S88
Ecarot, 1992, Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect., J Bone Miner Res, 7, 215, 10.1002/jbmr.5650070213
Xiao, 1998, Intrinsic mineralization defect in Hyp mouse osteoblasts, Am J Physiol, 275, E700
Mitnick, 1980, Calcium and phosphate metabolism in tumoral calcinosis., Ann Intern Med, 92, 482, 10.7326/0003-4819-92-4-482
Prince, 1982, Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations., Ann Intern Med, 96, 586, 10.7326/0003-4819-96-5-586
Topaz, 2004, Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis., Nat Genet, 36, 579, 10.1038/ng1358
Ishikawa, 2004, The expression pattern of UDP-N-acetyl-α-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma., J Surg Oncol, 86, 28, 10.1002/jso.20042
Yamashita, 2004, Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism., Eur J Endocrinol, 151, 55, 10.1530/eje.0.1510055
Benet-Pages, 2005, An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia., Hum Mol Genet, 14, 385, 10.1093/hmg/ddi034
Larsson, 2005, A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis., J Clin Endocrinol Metab, 90, 2424, 10.1210/jc.2004-2238
Araya, 2005, A novel mutation in fibroblast growth factor (FGF)23 gene as a cause of tumoral calcinosis., J Clin Endocrinol Metab, 90, 5523, 10.1210/jc.2005-0301
Larsson, 2005, FGF23 mutants causing familial tumoral calcinosis are differentially processed., Endocrinology, 146, 3883, 10.1210/en.2005-0431
Ruta, 1989, Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG)., Proc Natl Acad Sci USA, 86, 8722, 10.1073/pnas.86.22.8722
Ornitz, 1996, Receptor specificity of the fibroblast growth factor family., J Biol Chem, 271, 15292, 10.1074/jbc.271.25.15292
Werner, 1992, Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities., Mol Cell Biol, 12, 82, 10.1128/MCB.12.1.82
Yamashita, 2002, Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway., J Biol Chem, 277, 28265, 10.1074/jbc.M202527200
Ornitz, 2002, FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease., Genes Dev, 16, 1446, 10.1101/gad.990702
Deng, 1994, Murine FGFR-1 is required for early postimplantation growth and axial organization., Genes Dev, 8, 3045, 10.1101/gad.8.24.3045
Xu, 1998, Novel recognition motif on fibroblast growth factor mediates direct association and activation of SNT adapter proteins., J Biol Chem, 273, 17987, 10.1074/jbc.273.29.17987
Weinstein, 1998, FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung., Development, 125, 3615, 10.1242/dev.125.18.3615
Cancilla, 1999, Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney., Kidney Int, 56, 2025, 10.1046/j.1523-1755.1999.00781.x
Cancilla, 2001, Fibroblast growth factor receptors and their ligands in the adult rat kidney., Kidney Int, 60, 147, 10.1046/j.1523-1755.2001.00781.x
Floege, 1999, Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney., Kidney Int, 56, 883, 10.1046/j.1523-1755.1999.00637.x
Locatelli, 2002, Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia., Nephrol Dial Transplant, 17, 723, 10.1093/ndt/17.5.723
Silver, 2000, Molecular mechanisms of secondary hyperparathyroidism., Nephrol Dial Transplant, 15, 2, 10.1093/ndt/15.suppl_5.2
Imanishi, 2004, FGF-23 in patients with end-stage renal disease on hemodialysis., Kidney Int, 65, 1943, 10.1111/j.1523-1755.2004.00604.x
Shigematsu, 2004, Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency., Am J Kidney Dis, 44, 250, 10.1053/j.ajkd.2004.04.029
Hasegawa, 2004, Parathyroid-dependent and -indepedent mechanism to elevate serum concentration of FGF-23., J Am Soc Nephrol, 15, 267
Block, 1998, Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study., Am J Kidney Dis, 31, 607, 10.1053/ajkd.1998.v31.pm9531176
Slatopolsky, 1999, The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure., Am J Med Sci, 317, 370, 10.1016/S0002-9629(15)40549-X
Almaden, 1998, High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro., J Am Soc Nephrol, 9, 1845, 10.1681/ASN.V9101845
Gray, 1983, Dietary phosphate deprivation increases 1,25-dihyroxyvitamin D3 synthesis in rat kidney in vitro., J Biol Chem, 258, 1152, 10.1016/S0021-9258(18)33172-7
Hughes, 1975, Regulation of serum 1α,25-dihydroxyvitamin D3 by calcium and phosphate in the rat., Science, 190, 578, 10.1126/science.1188357
Portale, 1987, Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D., J Clin Invest, 80, 1147, 10.1172/JCI113172
Sato, 2004, Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism., Am J Kidney Dis, 44, 481, 10.1016/S0272-6386(04)00817-0
Shimada, 2005, Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism, Am J Physiol Renal Physiol, 289, F1088, 10.1152/ajprenal.00474.2004
Bai, 2003, Early lethality in Hyp mice with targeted deletion of the Pth gene, J Bone Miner Res, 18, S170
Nakanishi, 2005, Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients., Kidney Int, 67, 1171, 10.1111/j.1523-1755.2005.00184.x
Kazama, 2005, Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients., Kidney Int, 67, 1120, 10.1111/j.1523-1755.2005.00178.x
Schwindinger, 1992, Identification of a mutation in the gene encoding the α subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome., Proc Natl Acad Sci USA, 89, 5152, 10.1073/pnas.89.11.5152
Weinstein, 1991, Activating mutations of the stimulatory G protein in the McCune-Albright syndrome., N Engl J Med, 325, 1688, 10.1056/NEJM199112123252403
Albright, 1937, Rickets resistant to vitamin D therapy., Am J Dis Child, 54, 529
Collins, 2001, Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia., J Bone Miner Res, 16, 806, 10.1359/jbmr.2001.16.5.806
Yamamoto, 2005, The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome., J Bone Miner Metab, 23, 231, 10.1007/s00774-004-0589-9
White, 2005, Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation., Am J Hum Genet, 76, 361, 10.1086/427956
Lovejoy Jr, 1973, Linear nevus sebaceous syndrome: report of two cases and a review of the literature., Pediatrics, 52, 382, 10.1542/peds.52.3.382
Mehregan, 1973, Generalized follicular hamartoma. Complicated by multiple proliferating trichilemmal cysts and palmar pits., Arch Dermatol, 107, 435, 10.1001/archderm.1973.01620180085028
Brodsky, 1997, Oculocerebral dysgenesis in the linear nevus sebaceous syndrome., Ophthalmology, 104, 497, 10.1016/S0161-6420(97)30285-1
Carey, 1986, Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia., J Pediatr, 109, 994, 10.1016/S0022-3476(86)80283-9
Hoffman, 2005, Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome., Am J Med Genet A, 134, 233, 10.1002/ajmg.a.30599